Kristen Quigley
Chief Operating Officer bei MOLECULAR TEMPLATES, INC.
Profil
Kristen Quigley is currently the Chief Operating Officer at Molecular Templates, Inc. She started this position in 2023.
Prior to her current role, she worked as the Executive Director-Clinical Operations at Threshold Pharmaceuticals, Inc. Ms. Quigley completed her undergraduate degree at Washington University in St. Louis.
Aktive Positionen von Kristen Quigley
| Unternehmen | Position | Beginn |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Chief Operating Officer | 02.08.2023 |
Ehemalige bekannte Positionen von Kristen Quigley
| Unternehmen | Position | Ende |
|---|---|---|
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Chief Operating Officer | - |
Ausbildung von Kristen Quigley
| Washington University in St. Louis | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
